Hypersomnia Epidemiology Forecast 2024-2032

Hypersomnia Epidemiology Forecast Report Coverage

Expert Market Research's “Hypersomnia Epidemiology Forecast Report 2024-2032” offers comprehensive information on the prevalence and demographics of hypersomnia. It projects the future incidence and prevalence rates of hypersomnia across various populations. The study covers age, gender, and type as major determinants of the hypersomnia-affected population. The report highlights patterns in the prevalence of hypersomnia over time and projects future trends based on multiple variables.

Hypersomnia Disease Overview

Hypersomnia or excessive daytime sleepiness is a neurological disorder that causes the inability to stay awake and alert during the day despite adequate nighttime sleep. This condition can be caused by sleep disorders, medications, inadequate sleep, medical or psychiatric illnesses, depression, and head injury, among others. The characteristics of hypersomnia differ from person to person depending on the underlying causes, age, and lifestyle.

Hypersomnia: Treatment Overview

Medications and lifestyle changes are the primary treatments for hypersomnia. Modafinil (Provigil) is a common stimulant that is prescribed to the patients to help them stay awake during the day. Armodafinil (Nuvigil) is another medication for the treatment of idiopathic hypersomnia. Psychostimulants such as amphetamine and methylphenidate are also prescribed but they carry more abuse potential and side effects than first-line agents.

Epidemiology

The hypersomnia epidemiology section offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for hypersomnia by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for hypersomnia and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• Hypersomnia is estimated to affect approximately 5% of the population, with a family history present in around 39% of the patients struggling with idiopathic hypersomnia.
• The prevalence of idiopathic hypersomnia falls in the range of 0.002% to 0.010% in the general population, with a greater number of cases reported in women.
• A 2018 study conducted in a sample of 6,483 adolescents aged 13-18 years revealed that about 41.5% of adolescents in the United States feel sleepy during the daytime, with 11.7% meeting hypersomnolence criteria.
• The prevalence of idiopathic hypersomnia is estimated to slightly less frequent in expert centers compared to narcolepsy, affecting around 1 to 2 persons for 10,000 inhabitants.

Country-wise Hypersomnia Epidemiology

The hypersomnia epidemiology data and findings for the United States, EU-4 (Germany, Spain, Italy, France), the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of hypersomnia varies between countries owing to the differences in work culture, lifestyle, and environmental factors such as sleep hygiene, levels of stress, or prevalence of comorbid conditions like depression. Genetic factors, as well as differences in age, gender, and ethnicity, also contribute to variations in the prevalence of hypersomnia between countries. In the United States, a 2023 study reported the prevalence rate of idiopathic hypersomnia to be 32.12, 35.71, and 37.03 per 100,000 persons in 2019, 2020, and 2021, respectively.

Country Specific Stats:

Scope of the Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of hypersomnia based on several factors.
• Hypersomnia Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The report helps to identify the patient population and the unmet needs of hypersomnia are highlighted along with an assessment of the disease's risk and burden.

Key Questions Answered

• What are the key findings of hypersomnia epidemiology in the 8 major markets?
• What will be the total number of patients with hypersomnia across the 8 major markets during the forecast period?
• What was the country-wise prevalence of hypersomnia in the 8 major markets in the historical period?
• Which country will have the highest number of hypersomnia patients during the forecast period of 2024-2032?
• Which key factors would influence the shift in the patient population of hypersomnia during the forecast period of 2024-2032?
• What are the currently available treatments for hypersomnia?
• What are the disease risks, signs, symptoms, and unmet needs of hypersomnia?

Related Reports

Chronic Insomnia Epidemiology Forecast